ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INZY Inozyme Pharma Inc

7.39
0.00 (0.00%)
Pre Market
Last Updated: 04:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 6.87
Ask Price 8.00
News -
Day High

Low
2.689

52 Week Range

High
7.5599

Day Low
Company Name Stock Ticker Symbol Market Type
Inozyme Pharma Inc INZY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 7.39 04:00:00
Open Price Low Price High Price Close Price Prev Close
7.39
Trades Volume Avg Volume 52 Week Range
0 0 - 2.689 - 7.5599
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 7.39 USD

Inozyme Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
456.49M 61.77M - 0 -67.06M -1.09 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Inozyme Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No INZY Message Board. Create One! See More Posts on INZY Message Board See More Message Board Posts

Historical INZY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.057.55995.766.65948,6591.3422.15%
1 Month6.647.55995.466.22696,2510.7511.30%
3 Months4.197.55994.035.72533,0513.2076.37%
6 Months4.507.55992.6894.75472,4882.8964.22%
1 Year3.657.55992.6895.15585,4363.74102.47%
3 Years18.56521.990.9914.61383,730-11.18-60.19%
5 Years17.9331.64990.9915.35326,203-10.54-58.78%

Inozyme Pharma Description

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Your Recent History

Delayed Upgrade Clock